PT - JOURNAL ARTICLE AU - Peter Ueda AU - Thomas Wai-Chun Lung AU - Philip Clarke AU - Goodarz Danaei TI - Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis AID - 10.3399/bjgp17X692141 DP - 2017 Sep 01 TA - British Journal of General Practice PG - e598--e608 VI - 67 IP - 662 4099 - http://bjgp.org/content/67/662/e598.short 4100 - http://bjgp.org/content/67/662/e598.full SO - Br J Gen Pract2017 Sep 01; 67 AB - Background The 2014 guidelines on cardiovascular risk assessment and lipid modification from the National Institute for Health and Care Excellence (NICE) recommend statin therapy for adults with prevalent cardiovascular disease (CVD), and for adults with a 10-year CVD risk of ≥10%, estimated using the QRISK2 algorithm.Aim To determine risk factor levels required to exceed the risk threshold for statin therapy, and to estimate the number of adults in England who would require statin therapy under the guidelines.Design and setting Cross-sectional study using a sample representative of the English population aged 30–84 years.Method To estimate 10-year CVD risk different combinations of risk factor levels were entered into the QRISK2 algorithm. The NICE guidelines were applied to the sample using data from the Health Survey for England 2011.Results Even with optimal risk factor levels, males of different ethnicities would exceed the 10% risk threshold between the ages of 60 and 70 years, and females would exceed the threshold between 65 and 75 years. Under the NICE guidelines, 11.8 million males and females (37% of the adults aged 30–84 years) would require statin therapy, most of them (9.8 million) for primary prevention. When analysed by age, 95% of males and 66% of females without CVD in ages 60–74 years, including all males and females in ages 75–84 years, would require statin therapy.Conclusion Under the 2014 NICE guidelines, 11.8 million (37%) adults in England aged 30–84 years, including almost all males >60 years and all females >75 years, require statin therapy.